Clinical Trial Update: Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 trial update of subcutaneous icatibant for acute attacks in hereditary angioedema; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2014-06-09